2018 AANS Annual Scientific Meeting-J. Douglas Miller Lecture: A Novel Drug for the Treatment of Traumatic Brain Injury

J. Douglas Miller Lecture: A Novel Drug for the Treatment of Traumatic Brain Injury

Video Transcription

Video Summary

Dr. Howard Eisenberg, a neurosurgeon and researcher at the University of Maryland, delivered the J. Douglas Miller Lecture on the topic of traumatic brain injury. He discussed the search for a drug to improve outcomes in brain injury cases, highlighting the failure of previous trials and the need for a better understanding of the condition and trial methodology. Dr. Eisenberg introduced a novel cell surface membrane ion channel that is upregulated following injury and proposed it as a potential target for treatment of brain injury. He explained the mechanics of the channel and its role in causing cell death and hemorrhagic contusions. Preclinical studies in animal models showed promising results with the drug glyburide, which was able to block the channel and reduce injury. Dr. Eisenberg presented the findings of two Phase II clinical trials, one for traumatic brain injury and another for ischemic stroke. The trials showed positive trends in reducing edema and improving patient outcomes. He emphasized the potential of repurposing glyburide, a drug commonly used for diabetes treatment, as a therapy for brain injury. However, he acknowledged the limitations of the studies and highlighted the need for further research. The lecture concluded with a discussion on the future directions of studying this channel and its potential as a target for drug development. Attribution: Dr. Howard Eisenberg, J. Douglas Miller Lecture on Traumatic Brain Injury, University of Maryland.

Asset Caption

Howard M. Eisenberg, MD, FAANS

Keywords

traumatic brain injury

drug

cell surface membrane ion channel

glyburide

clinical trials

improving patient outcomes

repurposing